0001621443-14-000001.txt : 20141009 0001621443-14-000001.hdr.sgml : 20141009 20141009161838 ACCESSION NUMBER: 0001621443-14-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20141009 DATE AS OF CHANGE: 20141009 EFFECTIVENESS DATE: 20141009 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Zynerba Pharmeceuticals, Inc. CENTRAL INDEX KEY: 0001621443 IRS NUMBER: 260389433 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-226158 FILM NUMBER: 141150323 BUSINESS ADDRESS: STREET 1: 900 SOUTH LIMESTONE STREET STREET 2: ROOM 459 CITY: LEXINGTON STATE: KY ZIP: 40536 BUSINESS PHONE: 610-263-0163 MAIL ADDRESS: STREET 1: 900 SOUTH LIMESTONE STREET STREET 2: ROOM 459 CITY: LEXINGTON STATE: KY ZIP: 40536 D 1 primary_doc.xml X0707 D LIVE 0001621443 Zynerba Pharmeceuticals, Inc. 170 N. Radnor-Chester Road Suite 350 Radnor PA PENNSYLVANIA 19087 610-263-0163 DELAWARE AllTranz, Inc. None Corporation true Armando Anindo c/o Zynerba Pharmaceuticals, Inc. 170 N. Radnor-Chester Road, Suite 350 Radnor PA PENNSYLVANIA 19087 Executive Officer Director Steven Gailar c/o Zynerba Pharmaceuticals, Inc. 170 N. Radnor-Chester Road, Suite 350 Radnor PA PENNSYLVANIA 19087 Director Philip Wagenheim c/o Zynerba Pharmaceuticals, Inc. 170 N. Radnor-Chester Road, Suite 350 Radnor PA PENNSYLVANIA 19087 Director Terri B. Sebree c/o Zynerba Pharmaceuticals, Inc. 170 N. Radnor-Chester Road, Suite 350 Radnor PA PENNSYLVANIA 19087 Executive Officer Suzanne Hanlon c/o Zynerba Pharmaceuticals, Inc. 170 N. Radnor-Chester Road, Suite 350 Radnor PA PENNSYLVANIA 19087 Executive Officer Pharmaceuticals Decline to Disclose 06b false 2014-09-24 false true true true false 0 Broadband Capital Management, LLC 48001 None None 712 Fifth Avenue 22nd Floor New York NY NEW YORK 10019 CA CALIFORNIA CO COLORADO CT CONNECTICUT FL FLORIDA MD MARYLAND NY NEW YORK NC NORTH CAROLINA PA PENNSYLVANIA SC SOUTH CAROLINA WI WISCONSIN false 13000000 7309180 5690820 false 30 0 0 The Placement Agent was reimbursed for expenses incurred in connection with the offering and received cash and stock for services to the company including financial advisory, management consulting and executive recruitment. 0 A portion of the proceeds will be used to pay expenses and fees disclosed in Item 15 to the Placement Agent, which is associated with one of the company's directors. false Zynerba Pharmeceuticals, Inc. Armando Anido Armando Anido Chairman of the Board and Chief Executive Officer 2014-10-09